



LKT Laboratories, Inc.

Tivozanib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID T3585

CAS No. 475108-18-0

Chemical Name

Synonym AV-951

Formula $C_{22}H_{19}ClN_4O_5$

Formula Wt. 454.86

Melting Point


Purity $\geq 98\%$

Solubility

Store Temp Ambient

Ship Temp Ambient

Description Tivozanib is an anticancer chemotherapeutic and anti-angiogenic compound that inhibits VEGFR1/2/3, c-Kit, and PDGFR. Tivozanib is currently in clinical trials as a potential treatment for renal cell carcinoma. The antiangiogenic activity of tivozanib is exhibited by its ability to suppress development of choroidal neovascular (CNV) lesions and also to regress established CNV in animal models.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
T3585	5 mg	\$112.40
T3585	10 mg	\$173.90
T3585	25 mg	\$367.90

References Cowey CL. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. *Drug Des Devel Ther.* 2013 Jun 21;7:519-27. PMID: 23818763.

Hegpur M, Sadeghi S, Dorff TB, et al. Tivozanib in the treatment of renal cell carcinoma. *Biologics.* 2013;7:139-48. PMID: 23788831.

Kang S, Roh YJ, Kim IB. Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice. *Exp Eye Res.* 2013 Jul;112:125-33. PMID: 23701975.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.